Winners Boohoo View Beat, Abingdon Deal Wins, Abingdon 2026

Key Points

• Boohoo Group Plc expected to beat profit forecasts for the year, with analysts raising expectations ahead of results.
• Abingdon Health Plc wins major commercial deals for its rapid tests, boosting shares significantly.
• LSE’s “Winners & Losers” column spotlights Boohoo’s positive outlook and Abingdon’s contract successes.
• Boohoo’s revenue guidance upgraded; potential for share price rally post-results.
• Abingdon secures deals with undisclosed partners for its COVID-19 and other rapid diagnostic tests.
• Broader market context: Fashion retail recovery signals amid economic pressures.
• No specific loser details in primary coverage, but focus on standout performers.
• Shares in Abingdon surged over 20% on deal announcements.
• Boohoo’s CEO outlook remains optimistic despite challenges.
• Story reported from LSE.co.uk, dated around March 2026 market close.

Abingdon (Manchester Mirror) March 30, 2026 – Boohoo Group Plc is poised to surpass analyst profit expectations for the fiscal year, while local diagnostics firm Abingdon Health Plc celebrates fresh commercial victories that propelled its shares higher, as highlighted in the London Stock Exchange’s latest winners and losers roundup.

What Makes Boohoo Set to Beat Profit Views?

Analysts have upped their forecasts for Boohoo, the online fashion retailer, anticipating it will exceed profit guidance when full-year results land soon. As reported by James Thompson of LSE.co.uk in the article “WINNERS & LOSERS: boohoo to beat view; Abingdon Health wins deals,” market watchers now pencil in stronger-than-expected earnings. “Boohoo is on track to beat views,” Thompson noted, citing upgraded revenue projections from key brokers.

Boohoo’s management has guided for full-year revenue growth, navigating a tough retail landscape marked by inflation and shifting consumer habits. Sources close to the company, per LSE coverage, indicate robust online sales momentum, particularly in core markets like the UK and US. “The group has outperformed peers in cost control,” stated analyst Jane Hargreaves of City firm Shore Capital, as quoted by Thompson. This positions Boohoo for a potential share price lift post-results, with shares trading at a discount to historical multiples.

The upbeat sentiment stems from resilient demand for affordable fashion amid economic headwinds. Boohoo’s platform, encompassing brands like PrettyLittleThing and Nasty Gal, benefits from agile supply chains and data-driven inventory management. No official comment from Boohoo was available at press time, but investor briefings have reinforced confidence.

How Did Abingdon Health Secure These Major Deals?

Abingdon Health Plc, a York-based diagnostics specialist with operations resonating in Abingdon’s biotech scene, announced multiple commercial wins for its rapid testing kits. Shares rocketed more than 20% on the news, making it a clear LSE winner. As detailed by James Thompson of LSE.co.uk, “Abingdon Health wins deals,” spotlighting contracts for its suite of lateral flow tests, including COVID-19 and infectious disease panels.

The deals involve partnerships with global health firms, though specifics on partners remain confidential pending formal disclosures. “These agreements validate our technology platform,” said Chris Yates, CEO of Abingdon Health, in a statement attributed via LSE.co.uk. The contracts cover supply of over 1 million test units initially, with options for expansion. Abingdon’s BerganBIO platform enables quick development of point-of-care diagnostics, a boon in post-pandemic health monitoring.

Further attribution from Thompson’s piece reveals the wins build on prior successes, such as UK government contracts during the pandemic. “Abingdon’s pipeline is accelerating,” Yates added, emphasising scalability. Shares closed at 12.5p, up sharply from recent lows, reflecting investor enthusiasm for revenue visibility.

Who Are the Standout Winners in LSE’s Latest Roundup?

The LSE’s Winners & Losers column, a daily staple for traders, crowned Boohoo and Abingdon as top performers amid a mixed session. James Thompson of LSE.co.uk reported no major losers highlighted in this edition, shifting focus to upward movers. Boohoo’s pre-results glow contrasted with sector peers struggling on margins.

Abingdon’s surge underscores diagnostics sector resilience. “Commercial traction is key for small caps like Abingdon,” noted analyst Mark O’Hara of Panmure Gordon, as cited by Thompson. Broader FTSE AIM index gained modestly, buoyed by health and retail plays.

Why Is Boohoo’s Revenue Outlook Being Upgraded?

Broker consensus has shifted positively for Boohoo. Peel Hunt analysts, per LSE.co.uk via Thompson, lifted revenue forecasts by 2% to £1.92 billion, citing margin expansion. “Strong black Friday trading sets the tone,” they wrote. Challenges persist, including returns rates and competition from Shein, but Boohoo’s Debenhams integration aids diversification.

John Pursglove, CFO, previously signalled in earnings calls: “We are focused on profitability.” This aligns with cost-saving measures slashing overheads by 15%.

What Do Abingdon’s New Deals Mean for Investors?

For Abingdon, the pacts promise recurring revenue. Chris Yates elaborated: “These deals de-risk our growth story,” per LSE attribution. The firm’s Dundee manufacturing hub ramps up to meet demand. Analysts eye further pipeline news, with shares now eyeing 18p targets.

How Does This Fit Broader Market Trends?

Fashion retail claws back ground as consumers favour value. Diagnostics thrive on global health vigilance. LSE data shows AIM index up 5% year-to-date, with Abingdon among leaders.

What Challenges Lie Ahead for Boohoo?

Despite the beat, Boohoo faces regulatory scrutiny on sustainability and worker conditions. “Execution risks remain,” cautioned Hargreaves.

Could Abingdon’s Wins Spark More Contracts?

Yates hinted at a robust pipeline: “Talks with major players ongoing.” This could double revenues in 2026.

Impacts on Local Abingdon Economy?

Abingdon’s biotech cluster benefits, with Abingdon Health employing locals and drawing investment. “A win for the region,” said councillor Laura Whitmore.